Table 2 Treatment approaches among patients with different virus shedding of COVID-19 infection
|  | Virus shedding < 14 days (N = 56) | Virus shedding ≥ 14 days (N = 69) | p |
|---|---|---|---|
| Â | No. (%) | ||
Disease severity | Â | Â | Â |
 Severe/critical N (%) | 8 (13.6%) | 20 (29.0%) | 0.24 |
Treatment approaches | Â | Â | Â |
 Treatment with Lobinavi/ritonavir alone | 6 (10.5%) | 8 (11.6%) | 0.86 |
 Treatment with Arbidol alone | 7 (12.2%) | 6 (8.7%) | 0.53 |
 Combined treatment of nebulized IFN-α with lopinavir–ritonavir | 18 (31.6%) | 9 (13.0%) | 0.03 |
 Combined treatment of nebulized IFN-α, with Arbidol | 1 (1.8%) | 5 (7.2%) | 0.16 |
 Combined treatment of nebulized IFN-α, lopinavir–ritonavir and Arbidol | 12 (21.1%) | 29 (42.0%) | 0.04 |
 Treatment with Oseltamivir phosphate alone | 3 (5.3%) | 3 (4.3%) | 0.81 |
 Treatment with moxifloxacin | 12 (21.1%) | 29 (42.0%) | 0.04 |
 Treatment with ribavirin | 5 (8.8%) | 6 (8.7%) | 0.99 |
 Treatment with Chinese traditional medicine (Xuebijing) | 15 (26.3%) | 29 (42.0%) | 0.14 |
 Treatment with Methylprednisolone | 3 (5.3%) | 15 (21.7%) | 0.01 |
 Treatment with γ-globulin | 0 | 3 (4.3%) | 0.12 |
Antiviral treatment course | Median (range) | p | |
|---|---|---|---|
|  | 9 (4–12) | 15 (7–19) | 0.14 |